Lung densities

Quibim

Quibim has developed an automated suite with a patented algorithm that analyzes CT volume datasets to quantify different imaging biomarkers: lung and vessel volumes, low densities volumes and their regional distribution, and 15th percentile of Hounsfield Units (HU) of the lungs. The tool enables to perform lung detection, mask extraction and fixed thresholding in CT volume datasets. The solution also provides quantitative data about the volumes of the lungs, vessels, emphysema and air trapping through their regional distribution. This data is quantified by thirds and enables to detect the affected regions at an early stage and to follow up patients with COPD, lung emphysema, fibrosis, air trapping and pulmonary hypertension.
Product specifications Information source: Vendor
Last updated: Nov. 19, 2021
General
Product name Lung densities
Company Quibim
Subspeciality Chest
Modality CT
Disease targeted COPD, lung emphysema, pulmonary hypertension, fibrosis, air trapping
Key-features Emphysema %, emphysema volume and lung volume
Suggested use Without interference of a radiologist: AI-only diagnosis
Data characteristics
Population Screening population
Input High resolution CT. Tranverse
Input format
Output One-page structured report: 3D reconstruction of the lungs + emphysema, 3D reconstruction of the lungs + vessel tree, lung and emphysema volume parameters
Output format DICOM Secondary Capture / PDF
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically, right after the image acquisition
Processing time > 10 minutes
Certification
CE
Certified, Class IIa , MDD
FDA
No or not yet
Market presence
On market since 01-2019
Distribution channels Alma HEALTH PLATFORM
Countries present (clinical, non-research use) 4
Paying clinical customers (institutes) 5+
Research/test users (institutes) 10+
Pricing
Pricing model License
Based on Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers